EPS for Genomic Health, Inc. (GHDX) forecasted at $-0.08

April 16, 2018 - By Theresa Judd

Genomic Health, Inc. (NASDAQ:GHDX) Corporate Logo
Big Money Sentiment decreased to 1.13 in Q4 2017. It has change of 1.19, from 2017Q3’s 2.32. The ratio turned negative due to Genomic Health, Inc. positioning: 18 sold and 35 reduced. 18 funds took stakes and 42 increased stakes. Investors holded 30.86 million in 2017Q3 but now own 31.21 million shares or 1.14% more.
Vanguard Grp Inc Inc reported 0% stake. Parallax Volatility Advisers Limited Partnership owns 0% invested in Genomic Health, Inc. (NASDAQ:GHDX) for 2,982 shs. First Savings Bank Of Omaha invested in 0.06% or 30,105 shs. Baker Bros Advisors Ltd Partnership reported 4.09% in Genomic Health, Inc. (NASDAQ:GHDX). 179,465 are owned by Geode Cap Mgmt Limited Co. State Farm Mutual Automobile Ins holds 350,741 shs. Plante Moran Advsr Limited Co owns 200 shs. Goldman Sachs Gp has invested 0% in Genomic Health, Inc. (NASDAQ:GHDX). California State Teachers Retirement Systems holds 0% or 31,137 shs. Manufacturers Life Insur The accumulated 15,854 shs or 0% of the stock. Jacobs Levy Equity Management Incorporated accumulated 112,090 shs or 0.07% of the stock. Loomis Sayles And Com Limited Partnership has 498,054 shs for 0.04% of their capital. Spark Inv Limited Company accumulated 82,400 shs. Dupont Capital Mngmt accumulated 32,253 shs. State Street, a Massachusetts-based fund reported 638,645 shs.

Genomic Health, Inc. had 13 insider sales and 0 insider purchases since December 12, 2017. This’s net activity of $3.40 million. Febbo Phillip G. had sold 4,942 shs worth $162,290. 20,000 shs were sold by Popovits Kimberly J, worth $630,000. The insider Vaughn James J sold 3,004 shs worth $102,406. $699,000 worth of Genomic Health, Inc. (NASDAQ:GHDX) was sold by Leber Laura on Thursday, December 14.

Genomic Health, Inc. (NASDAQ:GHDX)’s earnings report is awaited On May, 8., RTT reports. Analysts have expectation on stock’s EPS of $-0.08. That’s down 14.29 % from last year’s $-0.07 EPS. Wall Street forecasts -200.00 % negative EPS growth as of May, 8. The stock increased 0.88% or $0.29 during the last trading session, reaching $33.31.Genomic Health, Inc. has volume of 98,407 shares. Since April 17, 2017 GHDX has declined 2.07% and is downtrending. GHDX underperformed by 13.62% the S&P 500.

Genomic Health, Inc. (NASDAQ:GHDX) Ratings Coverage

In total 8 analysts cover Genomic Health (NASDAQ:GHDX). “Buy” rating has 1, “Sell” are 3, while 4 are “Hold”. 13% are bullish. 10 are the (NASDAQ:GHDX)’s analyst reports since October 20, 2017 according to StockzIntelligence Inc. On Wednesday, December 20 William Blair downgraded the shares of GHDX in report to “Hold” rating. The stock rating was maintained by Piper Jaffray with “Hold” on Thursday, March 8. On Friday, March 9 the firm has “Buy” rating given by Canaccord Genuity. On Friday, October 20 the firm has “Hold” rating by Jefferies given. On Wednesday, December 13 the stock of Genomic Health, Inc. (NASDAQ:GHDX) has “Sell” rating given by J.P. Morgan. On Wednesday, December 13 the rating was downgraded by JP Morgan to “Underweight”. On Tuesday, January 16 the company was maintained by Canaccord Genuity. On Wednesday, November 15 the stock has “Buy” rating by Canaccord Genuity.

Genomic Health, Inc. provides actionable genomic information to personalize cancer treatment decisions worldwide.The company has $1.18 billion market cap. It develops and commercializes genomic clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.Last it reported negative earnings. The firm offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit.

Genomic Health, Inc. (NASDAQ:GHDX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.